Good AI and Mekonos : Partnering to transform Synthetic Biology and Personalized Medicine

Congrats to the team at Mekonos for raising an oversubscribed $25 million Series A round to overcome pharma industry’s cell and gene therapy delivery hurdle. 

We are so honored to be investing alongside Novartis, Magnetar Capital, Section 32, Sands Capital, Debiopharma, Elementum, and TDK Ventures. 

As one of the earliest investors in the company, we cannot be more proud of everything you have accomplished. 

Thank you for including us in your journey in transforming synthetic biology and personalized medicine.